Revenues for the fiscal year ended 2017 increased 42% to $1,831,000 compared with prior year-end revenues of $1,289,000.
Commercialization Updates on PURE Control® and PURE® Hard Surface Antimicrobial Food Safety Solutions
SAN DIEGO--(BUSINESS WIRE)-- PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2017.
Summary of Results – Year End Operations
Revenues for the fiscal year ended 2017 increased 42% to $1,831,000 compared with prior year-end revenues of $1,289,000. Core food safety revenues for the year ended July 31, 2017 increased 79% as compared with food safety revenues in the fiscal year ended 2016. Gross margin decreased in F’17 to 61% as compared with 66% in F’16 as a result of product mix. Total operating costs and expenses for the fiscal years ended 2017 and 2016, were $7.8 million and $8.3 million, respectively. The fiscal year end net loss was ($6.3) million compared with ($14.4) million for fiscal year end 2016.
Update – Fiscal Q4
- Regulatory - May 2017, PURE received the final FDA Acknowledgement Letter allowing the use of PURE Control® up to 160 PPM in raw poultry processing.
- Governance - July 2017, PURE appointed food supply chain executive Janet Risi to its Board of Directors.
Update – Fiscal Q4 to Present
- August 2017, PURE Control antimicrobial was listed as a Safe and Suitable Ingredient in the USDA-FSIS Directive 7120.1 for Poultry Products, allowing immediate commercialization for pre-OLR and post chill applications, including parts processing.
- September 2017, a poultry processor initiated testing of PURE Control for poultry parts and achieved in plant results on parts that are superior to chemistries in use today, eliminating Salmonella with up to a 2.7 Log* reduction in bacteria.
- October 2017, PURE raised $2.8 million in gross proceeds from a successful warrant tender offer.
- October 2017, produce processor Taylor Farms initiated scale-up of PURE Control application in its Salinas, CA, plant.
- October 2017, successfully completed testing of a new superior, non-toxic, labor saving food transport sanitization solution using PURE® Hard Surface disinfectant with a leading foodservice distributor.
- Announced today, an agreement and a first order from iGPS Logistics, the largest plastic pallet supplier to the food industry, for a unique pallet sanitization solution.
Hank R. Lambert, Chief Executive Officer, said that, “During fiscal 2017, PURE Bioscience achieved a number of critical regulatory milestones for PURE Control and developed unique new food safety solutions leveraging PURE Hard Surface. Much of the essential groundwork has now been laid, allowing us to look to 2018 as the beginning of our ability to deliver meaningful financial results.
“The anticipated revenue stream is expected to drive PURE’s ability to reach cash flow breakeven by calendar Q4 2018,” continued Lambert. “We anticipate sales growth will include expanded sales of PURE Control to produce processors - combined with first sales and expanding use by poultry processors. Also, we look forward to increasing sales of PURE Hard Surface to restaurants and to manufacturers/processors for environmental disinfection. Today we announced our first order for our new food transport sanitization solution from iGPS for plastic pallet sanitization, opening up a new $50M US market for PURE Hard Surface. We anticipate additional orders for our transport solution this quarter (calendar Q4).”
2017 Fiscal Year End Financial Results Conference Call
The Participant Dial-In Number for the conference call is 1-631-891-4304. Participants should dial in to the call at least five minutes before 1:30pm PDT (4:30pm EDT) on October 27, 2016. The call can also be accessed “live” online at http://public.viavid.com/index.php?id=126260. A replay of the recorded call will be available for 90 days on the Company’s website (http://www.purebio.com/investors/events-presentations/). You can also listen to a replay of the call by dialing 1-844-512-2921 (international participants dial 1-412-317-6671) starting October 26, 2017, at 7:30pm EDT through November 2, 2017 at 11:59 pm EDT. Please use PIN Number 10003544.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
Forward-looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company’s current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE Control into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2017. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
*Log reduction is a mathematical term used to show the relative number of live microbes eliminated from a surface by disinfecting or cleaning. A 2-Log reduction can be best illustrated as having two zeros, meaning the number of germs is 100 times smaller.
| PURE Bioscience, Inc. Consolidated Statements of Operations | ||||||||||
| Year ended | ||||||||||
| July 31, | ||||||||||
| 2017 | 2016 | |||||||||
| Net product sales | $ | 1,831,000 | $ | 1,289,000 | ||||||
| Operating costs and expenses | ||||||||||
| Cost of goods sold | 760,000 | 441,000 | ||||||||
| Selling, general and administrative | 5,230,000 | 5,076,000 | ||||||||
| Research and development | 779,000 | 927,000 | ||||||||
| Share-based compensation | 1,070,000 | 1,902,000 | ||||||||
| Total operating costs and expenses | 7,839,000 | 8,346,000 | ||||||||
| Loss from operations | (6,008,000 | ) | (7,057,000 | ) | ||||||
| Other income (expense) | ||||||||||
| Fair value of derivative liabilities in excess of proceeds | — | (1,867,000 | ) | |||||||
| Change in derivative liabilities | (277,000 | ) | (5,481,000 | ) | ||||||
| Interest expense, net | (5,000 | ) | (10,000 | ) | ||||||
| Other income, net | 27,000 | 44,000 | ||||||||
| Total other expense | (255,000 | ) | (7,314,000 | ) | ||||||
| Net loss | $ | (6,263,000 | ) | $ | (14,371,000 | ) | ||||
| Basic and diluted net loss per share | $ | (0.10 | ) | $ | (0.25 | ) | ||||
| Shares used in computing basic and diluted net loss per share | 63,492,406 | 56,830,533 | ||||||||
| PURE Bioscience, Inc. Consolidated Balance Sheets | ||||||||||
| July 31, 2017 | July 31, 2016 | |||||||||
| Assets | ||||||||||
| Current assets | ||||||||||
| Cash and cash equivalents | $ | 1,640,000 | $ | 5,194,000 | ||||||
| Accounts receivable | 297,000 | 263,000 | ||||||||
| Inventories, net | 273,000 | 350,000 | ||||||||
| Restricted cash | 75,000 | 75,000 | ||||||||
| Prepaid expenses | 174,000 | 260,000 | ||||||||
| Total current assets | 2,459,000 | 6,142,000 | ||||||||
| Property, plant and equipment, net | 548,000 | 440,000 | ||||||||
| Patents, net | 822,000 | 980,000 | ||||||||
| Total assets | $ | 3,829,000 | $ | 7,562,000 | ||||||
| Liabilities and stockholders’ equity | ||||||||||
| Current liabilities | ||||||||||
| Accounts payable | $ | 426,000 | $ | 479,000 | ||||||
| Restructuring liability | 19,000 | 39,000 | ||||||||
| Accrued liabilities | 230,000 | 216,000 | ||||||||
| Derivative liabilities | 1,853,000 | 1,802,000 | ||||||||
| Total current liabilities | 2,528,000 | 2,536,000 | ||||||||
| Deferred rent | 11,000 | 3,000 | ||||||||
| Total liabilities | 2,539,000 | 2,539,000 | ||||||||
| Commitments and contingencies (See Note 4) | ||||||||||
| Stockholders’ equity | ||||||||||
| Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding | — | — | ||||||||
| Common stock, $0.01 par value: 100,000,000 shares authorized, 63,093,153 shares issued and outstanding at July 31, 2017, and 64,823,917 shares issued and outstanding at July 31, 2016 | 631,000 | 649,000 | ||||||||
| Additional paid-in capital | 110,141,000 | 107,593,000 | ||||||||
| Accumulated deficit | (109,482,000 | ) | (103,219,000 | ) | ||||||
| Total stockholders’ equity | 1,290,000 | 5,023,000 | ||||||||
| Total liabilities and stockholders’ equity | $ | 3,829,000 | $ | 7,562,000 | ||||||
| PURE Bioscience, Inc. Consolidated Statements of Stockholders’ Equity | ||||||||||||||||||||||
| Additional | Total | |||||||||||||||||||||
| Common Stock | Paid-In | Accumulated | Stockholders’ | |||||||||||||||||||
| Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||||
| Balance July 31, 2015 | 41,859,297 | $ | 420,000 | $ | 90,811,000 | $ | (88,848,000 | ) | $ | 2,383,000 | ||||||||||||
| Issuance of common stock in private placements, net | 17,777,772 | 177,000 | (177,000 | ) | — | — | ||||||||||||||||
| Share-based compensation expense - stock options | — | — | 358,000 | — | 358,000 | |||||||||||||||||
| Share-based compensation expense - restricted stock units | — | — | 1,544,000 | — | 1,544,000 | |||||||||||||||||
| Stock issued for services | 250,000 | 3,000 | 287,000 | — | 290,000 | |||||||||||||||||
| Warrant liability removed due to warrant exercise and cancellation | — | — | 13,550,000 | — | 13,550,000 | |||||||||||||||||
| Issuance of common stock upon vesting of restricted stock units | 2,075,000 | 21,000 | (21,000 | ) | — | — | ||||||||||||||||
| Issuance of common stock upon exercise of warrants | 2,861,848 | 28,000 | 1,241,000 | — | 1,269,000 | |||||||||||||||||
| Net loss | — | — | — | (14,371,000 | ) | (14,371,000 | ) | |||||||||||||||
| Balance July 31, 2016 | 64,823,917 | $ | 649,000 | $ | 107,593,000 | $ | (103,219,000 | ) | $ | 5,023,000 | ||||||||||||
| Issuance of common stock in private placements, net | 1,572,941 | 16,000 | 1,033,000 | — | 1,049,000 | |||||||||||||||||
| Share-based compensation expense - stock options | — | — | 968,000 | — | 968,000 | |||||||||||||||||
| Share-based compensation expense - restricted stock units | — | — | 102,000 | — | 102,000 | |||||||||||||||||
| Warrant liability removed due to warrant exercise | — | — | 226,000 | — | 226,000 | |||||||||||||||||
| Issuance of common stock upon vesting of restricted stock units | 150,000 | 1,000 | (1,000 | ) | — | — | ||||||||||||||||
| Issuance of common stock upon exercise of warrants | 346,295 | 3,000 | 182,000 | — | 185,000 | |||||||||||||||||
| Restricted stock unit cancellation | (3,800,000 | ) | (38,000 | ) | 38,000 | — | — | |||||||||||||||
| Net loss | — | — | — | (6,263,000 | ) | (6,263,000 | ) | |||||||||||||||
| Balance July 31, 2017 | 63,093,153 | $ | 631,000 | $ | 110,141,000 | $ | (109,482,000 | ) | $ | 1,290,000 | ||||||||||||
| PURE Bioscience, Inc. Consolidated Statements of Cash Flows | ||||||||||
| Year ended | ||||||||||
| July 31, | ||||||||||
| 2017 | 2016 | |||||||||
| Operating activities | ||||||||||
| Net loss | $ | (6,263,000 | ) | $ | (14,371,000 | ) | ||||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||
| Share-based compensation | 1,070,000 | 1,902,000 | ||||||||
| Amortization of stock issued for services | 144,000 | 225,000 | ||||||||
| Fair value of derivative liabilities in excess of proceeds | — | 1,867,000 | ||||||||
| Impairment of patents | — | 48,000 | ||||||||
| Depreciation and amortization | 276,000 | 219,000 | ||||||||
| Inventory write-off | 50,000 | — | ||||||||
| Change in fair value of derivative liabilities | 277,000 | 5,481,000 | ||||||||
| Changes in operating assets and liabilities: | ||||||||||
| Accounts receivable | (34,000 | ) | (74,000 | ) | ||||||
| Inventories | 27,000 | (143,000 | ) | |||||||
| Prepaid expenses | (58,000 | ) | (8,000 | ) | ||||||
| Accounts payable and accrued liabilities | (59,000 | ) | (131,000 | ) | ||||||
| Deferred rent | 8,000 | (6,000 | ) | |||||||
| Net cash used in operating activities | (4,562,000 | ) | (4,991,000 | ) | ||||||
| Investing activities | ||||||||||
| Investment in patents | (20,000 | ) | (15,000 | ) | ||||||
| Purchases of property, plant and equipment | (206,000 | ) | (390,000 | ) | ||||||
| Net cash used in investing activities | (226,000 | ) | (405,000 | ) | ||||||
| Financing activities | ||||||||||
| Net proceeds from the sale of common stock | 1,049,000 | 8,000,000 | ||||||||
| Net proceeds from the exercise of warrants | 185,000 | 1,269,000 | ||||||||
| Net cash provided by financing activities | 1,234,000 | 9,269,000 | ||||||||
| Net decrease and increase in cash and cash equivalents | (3,554,000 | ) | 3,873,000 | |||||||
| Cash and cash equivalents at beginning of year | 5,194,000 | 1,321,000 | ||||||||
| Cash and cash equivalents at end of year | $ | 1,640,000 | $ | 5,194,000 | ||||||
| Supplemental disclosure of cash flow information | ||||||||||
| Cash paid for taxes | $ | 7,000 | $ | 2,000 | ||||||
| Noncash Investing and Financing activities | ||||||||||
| Warrant liability removed due to settlements | $ | 226,000 | $ | 13,550,000 | ||||||
| Restricted stock unit cancelation | $ | 38,000 | $ | — | ||||||
| Fair value of warrant liability at issuance | $ | — | $ | 9,867,000 | ||||||
| Common stock issued for prepaid services | $ | — | $ | 290,000 | ||||||
View source version on businesswire.com: http://www.businesswire.com/news/home/20171026005279/en/
Contacts
PURE Bioscience, Inc.
Hank Lambert, 619-596-8600 ext.103
CEO
hlambert@purebio.com
or
Bibicoff + MacInnis, Inc.
Terri MacInnis, 818-379-8500
VP of IR
terri@bibimac.com
or
Redwood Investment Group
Tom Hemingway, 714-978-4425
tomh@redwoodfin.com
Source: PURE Bioscience, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20171026005279/en
